Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Mabsoft Therapeutics (Shanghai) Co., Ltd.

Clinicaltrial registered29 Oct 2026

Mabsoft Therapeutics (Shanghai) Co., Ltd.

29 Oct 2026: Trial registered · Phase Ia Study of MST-931 in Healthy Adult Subjects. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
29 Oct 2026
Title
Phase Ia Study of MST-931 in Healthy Adult Subjects
Conditions
Ankylosing Spondylitis (AS)
Phase
Phase 1
Study Type
Interventional
Status
Recruiting
Countries
Australia
Country
Australia
Reference
NCT07903493
Location
Australia
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Mabsoft Therapeutics (Shanghai) Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from Australia

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.